News | December 28, 2025
Briefs: CuraTeQ Biologics, Sigachi Industries and Natural Capsules
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Full approval will depend on verification of clinical benefit in a confirmatory trial
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
Subscribe To Our Newsletter & Stay Updated
